End-of-day quote. End-of-day quote  - 11/26
1.075AUD -7.73%

Starpharma Holdings Limited Announces New Data Demonstrating That SPL7013, the Antiviral Agent in VIRALEZE Nasal Spray

07/26/2021 | 07:50pm
Starpharma Holdings Limited announced new data demonstrating that SPL7013, the antiviral agent in VIRALEZE nasal spray, is active against the highly transmissible Delta variant of SARS-CoV-2, achieving more than 99.99% reduction of infectious virus in laboratory-based virucidal assays. The antiviral testing of SPL7013 was conducted in the laboratory of internationally recognised virologist, Professor Philippe Gallay, at The Scripps Research Institute in the US, where previous studies have also demonstrated potent antiviral and virucidal activity of SPL7013 against multiple variants of SARS-CoV-2, including the globally important Alpha, Beta and Gamma `Variants of Concern'. The Scripps Research Institute has previously been recognised as the most influential research institution in the world. The most recent testing also demonstrated potent virucidal activity of SPL7013 against the Kappa variant of SARS-CoV-2. For the Delta and Kappa variants, SPL7013 achieved >99.99% and >99.9% reduction of infectious virus, respectively, within 30 seconds of exposure. The virucidal activity of SPL7013 against the Delta and Kappa variants in the current assays is consistent with the activity demonstrated in the original US strain of SARS-CoV-2 (2019- nCoV/USA-WA1/2020) (i.e., >99.9% reduction of infectious virus vs virus control) 4. These new findings indicate that there is no loss of potency for SPL7013 against the Delta and Kappa variants compared with earlier strains of the virus. The consistency and retention of SPL7013's activity is thought to be due to its mechanism of action, which is not reliant on specific binding sites within the spike protein. The broad-spectrum activity of SPL7013 against multiple viruses and retention of activity in multiple coronavirus variants are important features for VIRALEZE, particularly as new variants continue to emerge and challenge global public health efforts.
© S&P Capital IQ 2021
Copier lien
3d ago